Strong performance in the biopharma segment has pushed Biocon net profit up by 18.65 per cent for the first quarter ended June 30, 2013.
The biotechnology major has posted a consolidated net profit of Rs. 93.50 crore during the first quarter compared with Rs 78.80 crore in the same period last fiscal.
Consolidated total income of the company also rose to Rs 700.69 crore from Rs 576.68 crore.
Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said: "The new organisation structure has enabled us to deliver superior results with the core business performing strongly."
She added that the current fiscal will see the company consolidate its various initiatives whilst it continues to make investments in biosimilars and novel molecules.